Ticker: TSX - TOS
Shares Outstanding: 73,000,906
QUEBEC CITY, Feb. 5, 2014 /CNW Telbec/ - TSO3 Inc. ("TSO3"), an innovator in low-temperature sterilization technology for medical
devices in healthcare settings, today announced that the Company has
been notified by the European Patent Office of its decision to grant a
patent applied for in 2010.
This patent describes a method for controlling condensation of hydrogen
peroxide (H2O2) when sterilizing medical devices with hydrogen peroxide, either used
alone or in combination with ozone or other chemistries. Several other
patent applications covering TSO3's technology are still pending in the United States, Europe, Japan and
elsewhere in the world. The Company has also been notified by the
Japanese and Australian Patent Offices of their intent to grant two of
these other patents.
"TSO3 applied for a portfolio of patents globally in order to protect its new
technology. The grant of this patent in Europe as well as the
notification of the intent to grant additional patents in Japan and
Australia is rewarding. We anticipate additional grants in Europe,
Japan, and USA as well as additional markets in the near future" stated
Mr. R.M. (Ric) Rumble, President and CEO. "Our unique Dynamic Sterilant Delivery SystemTM is core to our differentiation and its protection enhances the
Company's inherent value. Recently TSO3 announced additional patent application in this space targeting methods
to improve the compatibility of the sterilization process with delicate
medical devices", concluded Mr. Rumble.
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument
sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital
environment and offers an advantageous replacement solutions to other
low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts (including, without
limitation, those regarding the timing or outcome of any financing
undertaken by TSO3) are forward-looking statements that involve certain risks,
uncertainties and hypotheses, including, but not limited to, general
business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other risks and
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
SOURCE: TSO3 Inc.
For further information:
R.M. (Ric) Rumble
President and CEO
(418) 651-0003, Ext. 254